Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

There are no systemic treatments for patients with hepatocellular carcinoma (HCC) whose disease progresses during sorafenib treatment. We aimed to assess the efficacy and safety of regorafenib in patients with HCC who have progressed during sorafenib treatment.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet

Title: Lancet (London, England)

Publisher: Elsevier BV

ISSN (Electronic): 1474-547X

ISSN (Print): 0140-6736

Publication date (Electronic): January 07 2017

Volume: 389

Issue: 10064

Affiliations

[1 ] Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, IDIBAPS-Hospital Clínic de Barcelona, CIBERehd, Universitat de Barcelona, Catalonia, Spain. Electronic address: jbruix@clinic.ub.es.

[2 ] Chinese People's Liberation Army Cancer Center of Nanjing Bayi Hospital, Nanjing, China.

[3 ] Groupement Hospitalier Lyon Nord, Hepatology Unit, Lyon, France.

[4 ] Department of Medical and Surgical Sciences, University of Bologna, S Orsola-Malpighi Hospital, Bologna, Italy.

[5 ] Division of Gastroenterology and Hepatology, Taipei Veterans General Hospital, Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan.

[6 ] St Laszlo Teaching Hospital, Budapest, Hungary.

[7 ] Service d'Oncologie Médicale, Centre Eugène Marquis, Rennes, France.

[8 ] Department of Gastroenterology and Nephrology, Chiba University, Chiba, Japan.

[9 ] Department of Hepatology, Hôpital de la Pitié-Salpétrière, Assistance Publique-Hôpitaux de Paris and Université Pierre et Marie Curie, Sorbonne Universités, Paris, France.

[10 ] Russian Cancer Research Center n.a.N.Blokhin, Moscow, Russia.

[11 ] CHU Timone, Université de la Méditerranée, Marseille, France.

[12 ] Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.

[13 ] King's College Hospital NHS Foundation Trust, London, UK.

[14 ] Tianjin Medical University Cancer Hospital, Tianjin, China.

[15 ] INSERM 954, CHU de Nancy, Université de Lorraine, Nancy, France.

[16 ] Service d'Hépatogastroentérologie, CHU, Caen, France.

[17 ] Kindai University Faculty of Medicine, Osaka, Japan.

[18 ] Department of Medical Oncology, National Taiwan University Hospital, Taipei, Taiwan.

[19 ] Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, IDIBAPS-Hospital Clínic de Barcelona, CIBERehd, Universitat de Barcelona, Catalonia, Spain; Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.

[20 ] Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

[21 ] Bayer HealthCare SAS, Loos, France.

[22 ] Bayer Pharmaceuticals, Bayer Vital GmbH, Leverkusen, Germany.

[23 ] Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA.

[24 ] The First Affiliated Hospital (Xijing Hospital) of the Fourth Military Medical University, Xi'an, China.

Article

Publisher Item ID: S0140-6736(16)32453-9

DOI: 10.1016/S0140-6736(16)32453-9

PubMed ID: 27932229

SO-VID: 4ce7a8ec-26e4-44e7-9ed6-0b15ee5181d6

History

Data availability:

Comments

Comment on this article

scite_

Cited by 1,434

See all cited by

- Version 1